Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Stock Quote

NASDAQTROV
$1.44
NASDAQTROV
Open
$1.54
Change
-$0.12 (-7.69%)
Day's Range
$1.43 - $1.58
52-Week Range
$0.88 - $9.65
Volume
178.0K
Market Cap
$11.1M